This post was originally published on this site
Healthineers said revenue at Varian, the U.S. cancer treatment specialist it bought earlier this year in a $16.4 billion deal, should grow between 9% and 12% each year with operating return on sales rising to well over 20% until 2025.
The company raised its synergy targets from the Varian takeover to more than 350 million euros ($396 million) by 2025, from a previous goal of 300 million euros.
Shares in Healthineers were up 4.8% at 0822 GMT, topping the German blue-chip index.
It expects annual comparable revenue growth of 6%-8% between 2023 and 2025 for the group, up from the 5%-7% forecast it expected for the fiscal year 2022, excluding COVID-19 tests.
Earnings per share would rise 12%-15% each year between 2023 and 2025, it said, adding its dividend policy to distribute 50% to 60% of the net income would remain unchanged.
“With fiscal year 2022 we started the next chapter of strategy 2025,” Chief Executive Bernd Montag told the company’s Capital Markets Day.
Healthineers will focus more on fighting cancer, cardiovascular and neurovascular diseases, leveraging its market position in imaging and robotics.
($1 = 0.8842 euros)
